MImAbs is an R&D Platform for the generation and characterization of immunotherapy antibodies. By converting the most promising targets from academia, start-ups and industry into drug candidates and developing cutting-edge immunotechnologies, MImAbs allows research institutions, public technology transfer offices, biotech and biopharma companies to de-risk the development of next generation immunotherapies against cancer and inflammatory diseases, keeping one step ahead of the competition.
Located in the historical birthplace of Marseille Immunopôle, the MImAbs’ building homes a fully integrated suite of platforms covering all steps leading to preclinical proof-of-concept. All R&D projects are managed in an industrial mindset by a multi-disciplinary team of experts specifically dedicated to antibody engineering, biochemistry, bioproduction and immunopharmacology. MImAbs has also established and continues to set up strategic scientific and technological partnerships both with academia and industry, notably with CIPHE (Transgenic mouse model engineering and immunomonitoring).
MImAbs was created as an independent company in December 2020 by the acquisition of the assets of the demonstrator of immunotherapy MI-mAbs, founded in 2011, an academic laboratory of Aix-Marseille University.